SCHEMBL6227015

SCHEMBL6227015

O=C(Nc1cccc(Cl)c1)Nc1ccccc1F

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.71
KMT2A Q03164 7/20 0.71
MAPT P10636 5/20 0.71
HTT P42858 5/20 0.71
LMNA P02545 3/20 0.71
ALDH1A1 P00352 2/20 0.70
RAB9A P51151 8/20 0.69
NPC1 O15118 7/20 0.69
KDM4E B2RXH2 3/20 0.68
GAA P10253 1/20 0.64
ALOX15 P16050 1/20 0.64
HSD17B10 Q99714 1/20 0.64
SMN1; SMN2 Q16637 3/20 0.64
CA12 O43570 1/20 0.63
CA1 P00915 1/20 0.63
CA2 P00918 1/20 0.63
CA9 Q16790 1/20 0.63
GRIK1 P39086 2/20 0.62
POLB P06746 1/20 0.60
TRPV1 Q8NER1 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6436290 0.90 KMT2A (0.68) MEN1KMT2AMAPTHTTLMNA
SCHEMBL4301183 0.89 KMT2A (0.82) MEN1KMT2AMAPTHTTLMNA
SCHEMBL31054239 0.87 MEN1 (0.64) MEN1KMT2AMAPTHTTLMNA
SCHEMBL13666033 0.85 MEN1 (0.70) MEN1KMT2AMAPTHTTLMNA
SCHEMBL23831948 0.85 KMT2A (0.60) MEN1KMT2AMAPTHTTLMNA
SCHEMBL30105161 0.85 KMT2A (0.60) MEN1KMT2AMAPTHTTLMNA
SCHEMBL6227431 0.84 MEN1 (0.74) MEN1KMT2AMAPTHTTLMNA
SCHEMBL12218116 0.84 MEN1 (0.68) MEN1KMT2AMAPTHTTLMNA
SCHEMBL28564087 0.84 MEN1 (0.74) MEN1KMT2AMAPTHTTLMNA
SCHEMBL30589615 0.84 MEN1 (0.74) MEN1KMT2AMAPTHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900219-B2 ABCA-1 elevating compounds CV THERAPEUTICS, INC. (US) 2005-05-31 US disclosed
EP-1513534-A2 COMPOUNDS FOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS CV THERAPEUTICS, INC. (US) 2005-03-16 EP disclosed
US-20030220356-A1 ABCA-1 elevating compounds CV THERAPEUTICS, INC. 2003-11-27 US disclosed
WO-2003084544-A2 COMPOUNDS DOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS CV THERAPEUTICS, INC. (US) 2003-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220356-A1 ABCA-1 elevating compounds ABCD3, ABCE1, ABCB4 MEN1 4471/4885KMT2A 3796/4885MAPT 4100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.